Loading clinical trials...
Loading clinical trials...
Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens
Conditions
Interventions
CBLB502
Placebo
Locations
1
Russia
Federal State Budgetary Institution "State Scientific Center of Coloproctology named after A.N. Ryzhikh" Ministry of Health of the Russian Federation
Moscow, Russia
Start Date
November 1, 2015
Primary Completion Date
February 1, 2017
Completion Date
December 31, 2017
Last Updated
February 9, 2017
NCT06696768
NCT04704661
NCT05489211
NCT04657068
NCT06625775
NCT06607458
Lead Sponsor
BioLab 612 LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions